Abstracts Archive - Page 1508 of 2607 - ACR Meeting Abstracts

Abstract Number: 1811 • 2017 ACR/ARHP Annual Meeting
Lupus Patients, and Their Sisters, Have Higher Miscarriage Rates Than Healthy Women
Eliza Chakravarty¹, David Miklos², Nathan Pezant³, Fang Wu², Indra Adrianto⁴, R. Hal Scofield³, Joel M. Guthridge⁵, Courtney Montgomery⁴ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Hematology, Stanford University, Stanford, CA, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that primarily affects women during the childbearing years. Among its protean manifestation, pregnancy complications including…
Abstract Number: 1812 • 2017 ACR/ARHP Annual Meeting
Preeclampsia and Incident Cardiovascular Disease in SLE Pregnancy
Julia F Simard¹, Marios Rossides², Elizabeth V. Arkema³, Elisabet Svenungsson⁴, Anna-Karin Wikstrom⁵, Murray Mittleman⁶ and Jane E. Salmon⁷, ¹Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA, ²Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁵Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁶Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, ⁷Medicine/Rheumatology, Hospital of Special Surgery, New York, NY
Background/Purpose: Pre-pregnancy cardiovascular health has been associated with preeclampsia during pregnancy, as well as future cardiovascular disease (CVD). Preeclampsia is related to endothelial dysfunction, hypertension,…
Abstract Number: 1813 • 2017 ACR/ARHP Annual Meeting
Rates of Contraceptive Use and Unintended Pregnancy in Teen Girls Prescribed Teratogenic Medications
Kimberly Hays¹, Kit Simpson¹, David Bundy¹, Elizabeth Wallis¹ and Natasha M. Ruth², ¹Pediatrics, Medical University of South Carolina, Charleston, SC, ²Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Reproductive aged women with rheumatic diseases are often prescribed teratogenic medications. These medications pose a serious threat to the mother and fetus. Rates of…
Abstract Number: 1814 • 2017 ACR/ARHP Annual Meeting
Time Trends over a Decade Show Earlier Intensified Medication Strategies and Improved Outcomes in Canadians with Early Inflammatory Arthritis
Orit Schieir¹, Marie-France Valois², Susan J. Bartlett^3,4, Carol A Hitchon⁵, Janet E. Pope⁶, Gilles Boire⁷, Boulos Haraoui⁸, Diane Tin⁹, Carter Thorne¹⁰, Edward C. Keystone^11,12 and Vivian P. Bykerk^13,14, ¹Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ²McGill University, Montreal, QC, Canada, ³Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁸Institute de Rheumatologie, Montreal, QC, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Toronto, Newmarket, ON, Canada, ¹¹University of Toronto, Toronto, ON, Canada, ¹²Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹³Mount Sinai Hospital, Toronto, ON, Canada, ¹⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Treatment recommendations aim to improve outcomes in rheumatoid arthritis (RA) through early identification and a treat-to-target approach. We examined recent trends over the past…
Abstract Number: 1815 • 2017 ACR/ARHP Annual Meeting
Patterns of Methotrexate Use and Discontinuation in a U.S. Rheumatoid Arthritis Registry
Jeffrey R. Curtis¹, Gene Wallenstein², Liza Takiya³, David Gruben², Connie Chen⁴, Ying Shan⁵, Taylor Blachley⁵, Kimberly J Dandreo⁵ and Joel Kremer⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, New York, NY, ⁵Corrona, LLC, Southborough, MA, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Methotrexate (MTX) remains a cornerstone therapy in the management of rheumatoid arthritis (RA), but patterns of adherence, intolerance, and inadequate response are not well…
Abstract Number: 1816 • 2017 ACR/ARHP Annual Meeting
Sex Differences in Orthopedic Surgery Among Patients with Rheumatoid Arthritis
Michael Richter¹, Cynthia S. Crowson², Eric L. Matteson³ and Ashima Makol³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Despite a decline in the incidence of orthopedic surgeries for rheumatoid arthritis (RA) in recent years, joint replacement remains an option for patients with…
Abstract Number: 1817 • 2017 ACR/ARHP Annual Meeting
Abatacept Shows Better Sustainability Than TNF Inhibitors When Used Following Initial Biologic DMARD Failure in the Treatment of RA: 8 Years of Real-World Observations from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, L Bessette², E Alemao³, B Haraoui⁴, F Massicotte¹, M Mtibaa⁵, E Muratti⁵, Jean-Pierre Pelletier¹, R Postema⁶, Jean-Pierre Raynauld⁷, M-A Rémillard⁸, D Sauvageau¹, A Turcotte⁹, É Villeneuve¹ and L Coupal¹⁰, ¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d'ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁵Bristol-Myers Squibb, Montréal, QC, Canada, ⁶Bristol-Myers Squibb, Uxbridge, United Kingdom, ⁷Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁸Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁹Rheumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ¹⁰Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: In the absence of biomarkers predicting response to a specific therapy, the choice of second biologic is based mostly on habit and availability of…
Abstract Number: 1818 • 2017 ACR/ARHP Annual Meeting
Development of Abatacept- and Adalimumab-Specific Predictive Models of Response to Therapy in RA Using Data from a Head-to-Head Study
S Bandyopadhyay¹, MA Maldonado¹, R Ammar¹, Michael Schiff², Michael Weinblatt³, Roy Fleischmann⁴ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women’s Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Centre, Dallas, TX
Background/Purpose: Highly effective, targeted DMARD therapies with different mechanisms of action are available for RA. Translating precision medicine into clinical practice requires treatment-specific predictive models,…
Abstract Number: 1819 • 2017 ACR/ARHP Annual Meeting
Delay of Diagnosis and Treatment in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity
Caitrin Coffey¹, Cynthia S. Crowson², Elena Myasoedova³, Eric L. Matteson⁴ and John M. Davis III⁵, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Evidence supports a therapeutic window of opportunity in early rheumatoid arthritis (RA), during which DMARD therapy most effectively improves clinical outcomes. The 2010 ACR/EULAR…
Abstract Number: 1820 • 2017 ACR/ARHP Annual Meeting
Sustained Effectiveness after Remission Induction with Methotrexate and Step-Down Glucocorticoids in Patients with Early Rheumatoid Arthritis Following a Treat-to-Target Strategy after 2 Years
Veerle Stouten¹, Johan Joly², Diederik De Cock¹, Sofia Pazmino¹, Kristien Van der Elst^2,3, René Westhovens^1,2 and Patrick Verschueren^1,2, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ³KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: Remission induction with methotrexate (MTX) and a moderate-dose, step-down scheme of Glucocorticoids (GC), (COBRA Slim strategy), showed equally high remission rates at year 1…
Abstract Number: 1821 • 2017 ACR/ARHP Annual Meeting
Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study
Tsutomu Takeuchi¹, Mark C. Genovese², Boulos Haraoui³, Zhanguo Li⁴, Li Xie⁵, Rena Klar⁶, Ana Pinto Correia⁵, Susan Otawa⁵, Pedro Lopez-Romero⁷, Inmaculada de la Torre⁵, Terence P. Rooney⁵ and Josef S. Smolen⁸, ¹Keio University School of Medicine, Tokyo, Japan, ²Stanford University Medical Center, Palo Alto, CA, ³Institut de Rhumatologie de Montreal, Montreal, QC, Canada, ⁴Peking University People's Hospital, Beijing, China, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Quintiles IMS Holdings, Inc., Durham, NC, ⁷Europe Research Center, Eli Lilly and Company, Madrid, Spain, ⁸Medical University of Vienna, Vienna, Austria
Background/Purpose: In patients (pts) with active RA and inadequate response (IR) to DMARDs, phase 3 studies demonstrated efficacy of baricitinib (2-mg and 4-mg). Larger, more…
Abstract Number: 1822 • 2017 ACR/ARHP Annual Meeting
The Effect of Sarilumab in Combination with Dmards on Fasting Glucose and Glycosylated Hemoglobin in Patients with Rheumatoid Arthritis with and without Diabetes
Mark C. Genovese¹, Roy Fleischmann², Owen Hagino³, Chih-Chi Hu⁴, Claudia Pena-Rossi³, Jonathan Sadeh³, Neil M.H. Graham⁵, Erin K. Mangan⁵, Hubert van Hoogstraten⁴ and Thomas Mandrup-Poulsen⁶, ¹Stanford University Medical Center, Palo Alto, CA, ²Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ³Sanofi, Bridgewater, NJ, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶University of Copenhagen, Copenhagen, Denmark
Background/Purpose: IL-6 involvement has been reported in glucose metabolism.1-4 Sarilumab, a human mAb blocking the IL-6Rɑ, was evaluated for treatment of RA in 3 clinical…
Abstract Number: 1823 • 2017 ACR/ARHP Annual Meeting
Methotrexate Requires High Serum BAFF Levels to Prevent Immunization Against TNF-α Inhibitors
Samuel Bitoun¹, Pierre Dönnes², Aline Doublet³, Kimberly Florence⁴, Agnes Hincelin-Mery⁵, Gaetane Nocturne⁶, Mattieu Allez⁷, N Ruperto⁸, Marc Pallardy⁹ and Xavier Mariette¹⁰, ¹INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicëtre, France, ²SciCross AB, Skövde, Sweden, ³Department of Rheumatology, Kremlin-Bicêtre hospital INSERM U1184, Le Kremlin Bicêtre, France, ⁴Immunogenicity and Clinical Immunology, GlaxoSmithKline, King of Prussia, PA, ⁵Sanofi, Chilly-Mazarin, France, ⁶INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, ⁷Department of Gastroenterology, Hopital Saint-Louis, APHP, Paris, France, ⁸PRINTO Coordinating Centre, Genoa, Italy, ⁹Inflammation, Chimiokines et Immunopathologie, INSERM UMR 996, Faculté de Pharmacie, Chatenay Mallabry, France, ¹⁰Université Paris Sud, Paris, France
Background/Purpose: Immunization against TNF Inhibitors (TNFi) is observed in 30-50% of patients with inflammatory rheumatic diseases. With most TNFi, anti-drug antibodies (ADA) lead to rapid…
Abstract Number: 1824 • 2017 ACR/ARHP Annual Meeting
Evaluation of Pneumococcal and Tetanus Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Baricitinib: Results from a Long-Term Extension Trial Substudy
Kevin Winthrop¹, Clifton O. Bingham III², John D. Bradley³, Maher Issa³, Rena Klar⁴ and Cynthia E. Kartman³, ¹Oregon Health and Sciences University, Portland, OR, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles IMS Holdings, Inc., Durham, NC
Background/Purpose: Clinical guidelines recommend pneumococcal and tetanus vaccinations in patients (pts) with RA.1 Baricitinib (bari) is an oral, selective Janus kinase (JAK) 1/JAK 2 inhibitor…
Abstract Number: 1825 • 2017 ACR/ARHP Annual Meeting
Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis
Michaela Koehm¹, Michael Hofmann², Rasmus Lüthje², Matthew McIntosh³, Varghese Abraham³, Cem Gabay⁴, Arthur Kavanaugh⁵, Harald Burkhardt⁶ and Frank Behrens⁶, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ²Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ³Genentech, San Francisco, CA, ⁴SCQM, Geneva, Switzerland, Geneva, Switzerland, ⁵Medicine, University of California, San Diego, La Jolla, CA, ⁶Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany
Background/Purpose: Fluctuations in disease activity due to short-term situational effects and measurement errors are important considerations for evaluation of individual clinically meaningful therapeutic response in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].